Below are the most recent publications written about "Jurkat Cells" by people in Profiles.
-
B?ziat V, Rapaport F, Hu J, Titeux M, Bonnet des Claustres M, Bourgey M, Griffin H, Bandet ?, Ma CS, Sherkat R, Rokni-Zadeh H, Louis DM, Changi-Ashtiani M, Delmonte OM, Fukushima T, Habib T, Guennoun A, Khan T, Bender N, Rahman M, About F, Yang R, Rao G, Rouzaud C, Li J, Shearer D, Balogh K, Al Ali F, Ata M, Dabiri S, Momenilandi M, Nammour J, Alyanakian MA, Leruez-Ville M, Guenat D, Materna M, Marcot L, Vladikine N, Soret C, Vahidnezhad H, Youssefian L, Saeidian AH, Uitto J, Catherinot ?, Navabi SS, Zarhrate M, Woodley DT, Jeljeli M, Abraham T, Belkaya S, Lorenzo L, Rosain J, Bayat M, Lanternier F, Lortholary O, Zakavi F, Gros P, Orth G, Abel L, Pr?tet JL, Fraitag S, Jouanguy E, Davis MM, Tangye SG, Notarangelo LD, Marr N, Waterboer T, Langlais D, Doorbar J, Hovnanian A, Christensen N, Bossuyt X, Shahrooei M, Casanova JL. Humans with inherited T?cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy. Cell. 2021 07 08; 184(14):3812-3828.e30.
-
Hokello J, Lakhikumar Sharma A, Tyagi M. AP-1 and NF-?B synergize to transcriptionally activate latent HIV upon T-cell receptor activation. FEBS Lett. 2021 03; 595(5):577-594.
-
Makdasi E, Amsili S, Aronin A, Prigozhina TB, Tzdaka K, Gozlan YM, Ben Gigi-Tamir L, Sagiv JY, Shkedy F, Shani N, Tykocinski ML, Dranitzki Elhalel M. Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL. Mol Cancer Ther. 2020 02; 19(2):513-524.
-
Tomalka AG, Resto-Garay I, Campbell KS, Popkin DL. In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol. 2018; 9:2552.
-
Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, Kim J, Martinez-Escala E, Amankulor N, Pro B, Guitart J, Mendillo ML, Savas JN, Boggon TJ, Choi J. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood. 2017 09 21; 130(12):1430-1440.
-
Huang Y, Koues OI, Zhao JY, Liu R, Pyfrom SC, Payton JE, Oltz EM. cis-Regulatory Circuits Regulating NEK6 Kinase Overexpression in Transformed B Cells Are Super-Enhancer Independent. Cell Rep. 2017 03 21; 18(12):2918-2931.
-
Richard NP, Pippa R, Cleary MM, Puri A, Tibbitts D, Mahmood S, Christensen DJ, Jeng S, McWeeney S, Look AT, Chang BH, Tyner JW, Vitek MP, Odero MD, Sears R, Agarwal A. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia. Oncotarget. 2016 Dec 20; 7(51):84214-84227.
-
Shenoda BB, Alexander GM, Ajit SK. Hsa-miR-34a mediated repression of corticotrophin releasing hormone receptor 1 regulates pro-opiomelanocortin expression in patients with complex regional pain syndrome. J Transl Med. 2016 Mar 03; 14:64.
-
Kiel MJ, Sahasrabuddhe AA, Rolland DCM, Velusamy T, Chung F, Schaller M, Bailey NG, Betz BL, Miranda RN, Porcu P, Byrd JC, Medeiros LJ, Kunkel SL, Bahler DW, Lim MS, Elenitoba-Johnson KSJ. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S?zary syndrome. Nat Commun. 2015 09 29; 6:8470.
-
Frishman-Levy L, Shemesh A, Bar-Sinai A, Ma C, Ni Z, Frenkel S, Muench V, Bruckmueller H, Vokuhl C, Debatin KM, Eckert C, Stanulla M, Schrappe M, Campbell KS, Loewenthal R, Schewe DM, Hochman J, Meyer LH, Kaufman D, Cario G, Porgador A, Izraeli S. Central nervous system acute lymphoblastic leukemia: role of natural killer cells. Blood. 2015 May 28; 125(22):3420-31.